12:00 AM
 | 
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Additional Phase II data

Additional data from the double-blind, international Phase II BCT-001 trial in 111 patients with Behcet's disease showed that the mean number of oral ulcers at week 12, the primary endpoint, in patients receiving twice-daily 30 mg apremilast was 0.5 vs. 2.1 for placebo (p<0.0001). Additionally, a significantly greater proportion of patients receiving apremilast were free of oral ulcers at week 12 vs. placebo (71% vs. 29%, p<0.0001)....

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >